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Abstract: Coronary heart disease treatment with HMG-CoA reductase inhibitors has been very successful. There is increasing interest 
in adding other lipid lowering therapy, primarily as additional therapy onto HMG-CoA reductase therapy. This paper will examine two 
of the more popular secondary agents, ezetimibe and niacin, and describe their research data and potential for usefulness in further 
reducing cardiovascular events.
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Introduction
Coronary  Heart  Disease  (CHD)  remains  the  most 
significant health problem in the US and the developed 
world. Overall Cardiovascular Disease (CVD), which 
includes cardiac along with cerebrovascular disease 
like stroke, has been the leading cause of US mortality 
every year since 1900, except for 1918 in the midst 
of the severe flu epidemic.1 Indeed, data shows that, 
in  the  most  recently  reported  year  of  2004,  CVD 
accounted for 36.3% of all US deaths.1
While CVD is multifactorial in origin, we have 
been able to identify and to treat certain prominent 
risk  factors,  including  hypertension  and  hyperlipi-
demia. Indeed, these and other comprehensive treat-
ments  have  produced  a  significant  and  persistent 
decline in cardiovascular mortality rates for several 
decades.1
Of the various cardiovascular risk factors in the 
prevention and management of CHD, hyperlipidemia, 
or elevated blood cholesterol, is one of the more treat-
able issues in this problem.
Interest  in  the  treatment  of  elevated  cholesterol 
began in the 1970’s with the Coronary Drug Project, 
or CPD.2 This trial in high risk men used Clofibrate, 
the original fibric acid agent, in some patients or high 
dose niacin (3 grams daily) in a different group of 
patients. The treatment with high dose niacin showed 
no reduction in total or cardiac mortality, with only 
a  minor  improvement  in  a  secondary  endpoint  of 
non-fatal  Myocardial  Infarction  (MI).2  However, 
a  European  study  with  clofibrate  also  showed  a 
reduction only in non-fatal MI but not a reduction in 
mortality.3
A  different  US  trial,  the  LRC-CPPT  trial, 
evaluated cholestyramine, a resin binding agent, in 
primary patients, those with high risk but without 
pre-existing disease.4 This study did show a signifi-
cant reduction in the primary end-point of fatal and 
non-fatal MI. The final early cholesterol study was 
the  Helsinki  Heart  Study,  evaluating  gemfibrozil, 
a different fibrate, in high risk men who were with-
out pre-existing heart disease.5 This study also had 
no reduction in total or cardiac mortality, but only a 
reduction in non-fatal MI.5
The modest and equivocal results of these early 
studies  led  many  to  question  whether  cholesterol 
treatment would reduce coronary heart disease. How-
ever, the next generation of studies, with the newer 
agents,  the  HMG-CoA  Reductase  Inhibitors,  or 
statins, showed that significant cholesterol reduction 
could reduce a wide range of cardiovascular events.
HMG-coA Reductase Inhibitors
The HMG-CoA reductase inhibitors, or “statins” as 
they are frequently called, have revolutionized the 
management of cardiovascular disease. Their mecha-
nism of action involves the inhibition of the HMG 
reductase step in the production of cholesterol in the 
liver. This leads to a reduction of hepatic cholesterol 
levels, thus stimulating the Low Density Lipoprotein, 
or LDL-C, receptor sites on the hepatic cells. The 
stimulated  LDL-C  receptors  increase  their  binding 
of LDL-C in the blood stream, lowering the serum 
LDL-C levels. The degree of LDL-C lowering dif-
fers within the statin class, with the original agents, 
pravastatin  and  lovastatin  having  the  least  LDL-C 
Table 1. evidence for cholesterol reduction therapies.
statin therapy effect on lipids Indirect cardiac 
markers
cardiac event 
reductions
HMG-coA reductase Inhibitors “statins”
All agents ↓LDL-C 20%–63% 
HDL-C ↑3%–10% 
↓ or no effect  
atorvastatin
Yes, rosuvastatin 
Others N/A
Reductions 
seen with all 
agents and all 
Patient groups
ezetimibe ↓LDL-C 18% 
↑HDL-C 3%
Unsuccessful None proven
Niacin #1000 mg- LDL-C 
No effect; ↑HDL-C 10%–15% 
2000 mg -↓LDL-C 15% 
↑HDL-C 20%
↓Carotid intimal 
wall thickening
No clear 
evidence 
marginal  
evidence in 
two studiesNiacin or ezetimibe
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lowering, while the newer statins, rosuvastatin and 
atorvastatin,  produce  the  most  potent  lowering  of 
LDL-C. In addition to lowering LDL-C by anywhere 
from 20% to 63%, the statins also lower total cho-
lesterol and triglycerides by different amounts. All 
of the statins except atorvastatin also increase High 
Density  Lipoprotein,  or  HDL-C,  also  in  amounts 
that vary between the agents. Atorvastatin can also 
lower  HDL-C,  an  anomaly  that  is  not  completely 
understood.6
In a series of landmark clinical trails, the statins 
showed  an  unsurpassed  ability  to  reduce  a  wide 
range  of  cardiovascular  clinical  events,  including 
cardiovascular  mortality  and  even  total  mortality. 
These  trials  cover  both  patients  without  previous 
cardiac  disease  (“primary  prevention”)  and  those 
with  pre-existing  cardiac  disease  (“secondary  pre-
vention”). The original statin trial was the 4S trial. 
4S studied over 4000 Scandinavian men with pre-
  existing coronary heart disease (“secondary preven-
tion”) with simvastatin 20 or 40 mg versus placebo.7 
The statin treated patients had significant reductions 
in a wide variety of cardiovascular end points includ-
ing total mortality, fatal and non-fatal MI, and even 
stroke. Two  subsequent  pravastatin  studies,  CARE 
and LIPID, showed reductions in MI in secondary 
prevention patients with mid-range cholesterol.8,9
The Heart Protection Study, or HPS, was an extraor-
dinarily important British study. HPS enrolled over 
20,000 men and women with coronary or other vas-
cular  disease,  diabetes  mellitus,  or  very  high  risk 
  hypertension.10  However,  HPS  enrolled  patients 
based on their risk rather than on their LDL-C, and 
treated patients with simvastatin 40 mg or placebo. 
Patients receiving simvastatin had significant reduc-
tions in total mortality, cardiovascular mortality, fatal 
or non-fatal MI, and stroke. These benefits were seen 
in all groups of patients, regardless of their baseline 
  LDL-C.10  This  extraordinary  study  led  to  recom-
mendations that all high risk patients should receive 
aggressive statin therapy.
In “Primary Prevention” trials, the original study was 
the West of Scotland, or WOSCOPS, study, which eval-
uated over 6500 Scottish men with markedly elevated 
LDL-C and no previous coronary disease.11 Pravasta-
tin 40 mg versus placebo produced significant reduc-
tions in first MI and fatal MI, and nearly a significant 
reduction in total mortality. A US trial, the AFCAPS/
TEXCAPS study, evaluated US men and women with 
mid range LDL-C (about 150 mg/dl median) but with 
lower HDL-C.12 Lovastatin 20 or 40 mg versus placebo 
produced significant reductions in cardiac events, with 
a more significant reduction in patients with HDL-C 
,40 mg/dl at baseline.12,13 This trial therefore extended 
the benefit of statin treatment to patients with only 
moderate LDL-C elevations, and it also showed that 
statin monotherapy treatment is an effective therapy in 
patients with low HDL-C syndrome.
Furthermore, the ASCOT-LLA demonstrated that 
LDL-C reduction alone produced significant reduction 
in cardiac events. In ASCOT-LLA, over 10,000 men 
and women without heart disease were given atorvas-
tatin 10 mg versus placebo.14 The dose of atorvastatin 
used produced a 36% reduction in LDL-C but did not 
lead to an increase in HDL-C as we had seen in all the 
previous statin studies. The atorvastatin treatment led 
to a significant reduction in fatal and non-fatal MI, 
along with a reduction in stroke, further supporting 
the LDL-C hypothesis.
JUPITER,  the  most  recent  statin  study,  was  so 
successful that it was stopped early to avoid continu-
ing to treat the placebo patients with only placebo. 
JUPITER enrolled low to medium risk primary pre-
vention patients with an LDL-C of ,130 mg/dl, but 
with a moderate elevation (.2 mg/dl) in the Hs-CRP 
inflammation marker, and treated them with rosuvas-
tatin 20 mg versus placebo. The rosuvastatin treated 
patients had marked reductions of their LDL-C into 
the range of 55 mg/dl, compared to LDL-C levels 
of about 110 mg/dl in the placebo treated patients. 
The rosuvastatin treated patients had very   significant 
reductions  in  cardiac  events,  reductions  often  of 
around 50%, without significant side effects from the 
very low LDL-C.15
While  many  patients  and  practitioners  express 
concern about the safety of the statin agents, a care-
ful examination of the research shows that, as a class, 
they are extraordinarily safe. They can produce mod-
est elevation in liver enzymes, but there has never 
been a clearly documented case of liver failure pro-
duced by a statin, in contrast to a number of cases of 
liver failure from acetaminophen.16–18 While there is 
a risk of muscle problems with the statins, this risk 
is modest and usually manageable. The actual rate of 
true myalgia from statins is not clear, but it is prob-
ably relatively low and it is often confused with the Guthrie
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is important, since it emphasizes that many of the 
muscle  aches  attributed  to  statin  therapy  are  also 
seen at the same rate in comparable patients who are 
not on statin therapy, representing the “background” 
level of muscle aches seen in patients who need statin 
therapy.
Myopathy,  a  more  serious  condition  with  a 
CK . 10 times normal and muscle pain, is seen much 
less frequently than the less serious myalgia. In the 
HPS study myopathy occurred in about 10 cases per 
10,000 patients treated with simvastatin, as opposed 
to 4 cases per 10,000 patients in the placebo treated 
group.10 The risk of myopathy appears to increase 
significantly  with  the  80  mg  doses  of  each  of  the 
stains, indicating that it is clearly related to the milli-
grams of statin used.19 Rhabdomyolysis, a very severe 
muscle breakdown syndrome which can be fatal in as 
much as 50% of cases, is fortunately very rare, seen in 
only about one case per every seven million US statin 
prescriptions.20 Therefore, the statin class is, overall, 
extremely safe even in the widespread use that we are 
seeing at this time.
In summary, the statin treatment trials show that 
this class of agents is extremely successful in reduc-
ing  heart  attack  and  other  cardiovascular  events 
in at-risk patients. Clearly, much of this benefit is 
mediated through the lowering of LDL-C. However, 
whether the same degree of benefit would be seen 
with agents from the medication classes other than 
the statins is unproven and therefore a point of debate 
and conjecture.
Other Lipid Reduction Therapies
There are several other classes of agents, including 
the  fibrates,  resin  absorption  inhibitors,  ezetimibe, 
and niacin, that are available to treat lipid disorders. 
These agents are used as monotherapy and also in 
combination with statin therapy. This paper will dis-
cuss the pharmacology and clinical usefulness of two 
of them, ezetimibe, a cholesterol absorption inhibitor, 
and niacin, a B-vitamin.
ezetimibe
Ezetimibe has been marketed in combination with sim-
vastatin as Vytorin®, and also as Zetia® for use as mono-
therapy or to be taken along with other therapy such as 
other statins or even other lipid reducing agents.
Table 2. Titles of acronyms.
Medical acronyms:
  LDL-C: Low Density Lipoprotein
  HDL-C: High Density Lipoprotein
  HsCRP: Highly specific C-Reactive Protein
  CHD: Coronary Heart Disease
  CvD: Cardiovascular Disease
  MI: Myocardial Infarction
Introduction
  CPD: Coronary Drug Project
    LRC-CPPT: Lipid Research Council—Coronary 
Primary Prevention Trial
HMG-coA reductase inhibitor studies
  4 S: Scandinavian Simvastatin Survival Study Group
    LIPID: Long-Term Intervention with Pravastatin in 
Ischemic Disease
  CARe: Cholesterol and Recurrent events Study
  HPS: Heart Protection Study
    wOSCOPS: west of Scotland Coronary Protection 
Study
    AFCAPS /TeXCAPS: Air Force /Texas Coronary 
Atherosclerosis Prevention Study
    ASCOT-LLA: Anglo-Scandinavian Cardiac Outcomes 
Trial- Lipid Lowering Arm
    JUPITER: Justification for the Use of Statins in 
Prevention: an Intervention Trial evaluating Rosuvastatin
ezetimibe
    eNHANCe: effect of the Combination of ezetimibe and 
High Dose Simvastatin vs. Simvastatin Alone on the 
Atherosclerotic Process
      In Patients with Heterozygous Familial 
Hypercholesterolemia
  SeAS: Simvastatin and ezetimibe in Aortic Stenosis
    ARBITeR-6 HALTS: Arterial Biology effects for the 
Investigation of the Treatment effects of Reducing 
Cholesterol—6: HDL and LDL Treatment Strategies
    IMPROve-IT: Improve Reduction of Outcomes with 
Vytorin Efficacy International Trial
    SANDS: Stop Atherosclerosis in Native Diabetics Study
  SHARP: Study of Heart and Renal Protection
niacin
    AIM-HIGH: Atherothrombosis Intervention in Metabolic 
Syndrome with Low HDL/High Triglycerides and Impact 
on Global Health Initiatives
  CLAS: Cholesterol Lowering Atherosclerosis Study
    ARBITeR-2: Arterial Biology effects for the Investigation 
of the Treatment effects of Reducing Cholesterol—2
    HATS: HDL Atherosclerosis Treatment Study 
ARBITeR-3: Arterial Biology effects for the Investigation 
of the Treatment effects of Reducing Cholesterol—3
routine aches and pains that many of us have. In the 
most recent study, JUPITER, the rate of muscle aches 
was 16% in the rosuvastatin group and 15.4% in the 
placebo  group.15  This  type  of  comparison  against 
the muscle aches seen in the placebo treated patients Niacin or ezetimibe
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Financially,  Zetia®  and  Vytorin®  have  been 
significant success stories. In 2009, both Zetia® and 
Vytorin®  each  achieved  over  four  hundred  million 
dollars in sales in the US alone.21 However, recently, 
concern about whether the lowering of lipid values 
with ezetimibe will actually produce the same level 
of reduction of cardiac events seen with the statins 
has been raised. While the utilization of ezetimibe has 
been assumed to produce the same degree of reduction 
of cardiac events as statin therapy, that assumption 
remains unproven at this time. In this section, I will 
review the data on ezetimibe and try to place its use 
in its proper scientific place.
Mechanism of Action
Ezetimibe has a completely different   mechanism of 
cholesterol lowering than do the statins. Ezetimibe 
reduces cholesterol by inhibiting cholesterol absorp-
tion in the intestines. Ezetimibe targets the NPC1L1 
sterol transporter, located in the brush border epithe-
lium of the small intestine.22 Inhibition of this sterol 
transporter reduces intestinal absorption of cholesterol 
by 54%. This reduced cholesterol absorption leads to 
a reduction of intestinal cholesterol being transported 
into the liver, lowering hepatic cholesterol.22 Lower-
ing of hepatic cholesterol stimulates the clearing of 
cholesterol from the blood, with this final mechanism 
being similar to the mechanism of action with the 
statins.
effects on Lipid Levels
This  action  by  ezetimibe  results  in  a  noticeable 
improvement in the serum lipids, with the total cho-
lesterol reduced by 13%, the LDL-C by 19%, triglyc-
erides reduced by 8%, and with the HDL-C increased 
by  3%.22  Since  this  mechanism  is  completely  dif-
ferent from the cholesterol reduction of the statins, 
the effects of ezetimibe are additive to statin effects 
in  the  reduction  of  cholesterol  fractions.22  Similar 
effects  are  also  seen  when  ezetimibe  is  combined 
with fenofibrate.22
preparations of ezetimibe
Ezetimibe is available in a 10 mg dosage form, either as 
monotherapy or, probably more commonly, as additive 
therapy on top of statin medication. It is also available 
in multiple dosage preparations as combination therapy 
with simvastatin, marketed as Vytorin®, at simvastatin 
doses of 10 mg (Vytorin 10®), 20 mg (Vytorin 20®), 
40 mg (Vytorin 40®) or 80 mg (Vytorin 80®).
Efficacy of Ezetimibe
The question as to whether ezetimibe therapy, either as 
dual therapy along with statin treatment or as mono-
therapy,  will  reduce  MI  and  other  cardiovascular 
events remains a difficult and controversial question. 
Ezetimibe  was  brought  to  the  market,  and  enjoyed 
considerable sales success, on the assumption that the 
LDL-C lowering it produced would reduce cardiovas-
cular events to the same degree as seen with statin ther-
apy. However, assumptions are not facts, and medicine 
is frequently not logical, but instead is scientific. There-
fore, we would need direct evidence of ezetimibe’s 
ability to reduce cardiac events before we can assure 
our patients that taking it will reduce their risk of heart 
attack. There are many examples of logic being proven 
wrong in medicine, such as homocysteine.
As we remember, elevated homocysteine levels are 
associated with higher risk for cardiovascular disease. 
However, numerous studies have shown that lower-
ing homocysteine to normal levels with folic acid has 
no effect on the risk for cardiovascular events.23,24
Without any completed studies that would resolve 
whether ezetimibe therapy will lower cardiovascular 
events, we are forced to look at studies that utilize other 
measurements to estimate the efficacy of ezetimibe. 
There have been several studies recently that utilized 
B-mode ultrasound measurements of carotid intima-
media thickening as a surrogate for coronary artery 
risk. These studies need to be approached with cau-
tion, since there is no clear evidence that changes in 
carotid intima-media thickening might be predictive 
of cardiovascular risk.
ENHANCE  was  the  first  longer  term  study  of 
ezetimibe use. ENHANCE enrolled and randomized 
720 men and women with familial hypercholester-
olemia, with untreated LDL-C of about 318 mg/dL, 
to either simvastatin 80 mg with ezetimibe 10 mg 
versus simvastatin 80 mg and placebo.25 The study 
used  B-mode  ultrasound  to  measure  the  intima-
media thickening in the carotid and femoral arter-
ies. The patients receiving ezetimibe in addition to 
simvastatin  did  have  markedly  lower  LDL-C  than 
those  receiving  simvastatin  alone,  with  LDL-C  of Guthrie
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141 mg/dL versus 192 mg/dL. However, the addition 
of ezetimibe therapy did not show an improvement 
in intima thickening, which actually showed a non-
significant  worsening  in  the  ezetimibe  group.  The 
overall meaning of this study is unclear, at best, but it 
created some doubts as to the efficacy of ezetimibe to 
improve cardiovascular outcomes.
The second study was SEAS, which enrolled 1873 
patients with aortic stenosis but without known coro-
nary heart disease.26 Patients had a baseline LDL-C of 
139 mg/dL, well above the average LDL-C seen in the 
JUPITER trial. They were randomized to simvastatin 
40 mg plus ezetimibe 10 mg, versus placebo. Surpris-
ingly, the simvastatin/ezetimibe patients did not show a 
reduction in the primary combined end point, meaning 
that the study was not successful. This lack of success 
is particularly surprising, since one would have thought 
that, based on the Heart Protection Study, simvastatin 
40 mg alone should have reduced cardiac events.
The  final  study  looking  at  ezetimibe  was  the 
ARBITER 6—HALTS trial. This trial, published in 
November of 2009, is somewhat difficult to inter-
pret.27 The study enrolled 363 men and women, with 
known coronary heart disease or its risk equivalent 
(including diabetes mellitus, a 20% or more MI risk 
from the Framingham calculation, or an elevated cor-
onary calcium score). The patients were already on 
background statin therapy, predominantly simvasta-
tin and atorvastatin, and their LDL-C must have been 
,100 mg/dL, with an HDL-C of ,50 mg/dL in men 
and ,55 mg/dL in women. The patients were random-
ized to 10 mg of ezetimibe or extended release niacin, 
initially 500 mg at bedtime, to be titrated toward a 
target dose of 2000 mg at bedtime.
Ezetimibe therapy did reduce the LDL-C further, 
with an average reduction of 19.2%, with an accom-
panying reduction of HDL-C of 2.8 mg/dL (6.5%).
Extended release niacin reduced LDL-C by only 
12.4%,  but  it  increased  the  HDL-C  by  7.5  mg/dL 
(17.6%).
The primary endpoint, the change in the thickness of 
the mean carotid intima, was significantly improved in 
the niacin group as compared to the ezetimibe patients. 
Essentially, the carotid intima was basically unchanged 
by ezetimibe therapy, while it was improved by extended 
release niacin therapy.27 There was a reduction in car-
diovascular events in the niacin group as compared to 
the ezetimibe group, but the overall numbers of cardio-
vascular events was small (9 in 165 ezetimibe patients 
against 2 in 160 niacin patients). Adverse events were 
somewhat more common in the niacin patients, and 
there were three times as many patients withdrawing 
for medication side effects in the niacin group than in 
the ezetimibe group (3 versus 17).
The supporters of niacin therapy were as delighted 
with the results of ARBITER-6 as the enthusiasts for 
ezetimibe  were  concerned.  However,  we  all  must 
maintain  great  caution  to  avoid  over  interpreting 
these results. First, whether changes of carotid intima 
thickening have any predictive valued as a surrogate 
marker for cardiovascular events is totally unproven. 
Secondly, even though there were differences in car-
diovascular events between the groups, the study was 
so small and short that the overall numbers of events 
were quite small, and therefore inconclusive. Finally, 
the absence of a placebo control group makes over-
all interpretation of this trial very difficult. While the 
study is suggestive, it remains a preliminary project 
that needs to be confirmed in a larger, longer trial to 
evaluate cardiovascular events and these therapies.
For  ezetimibe,  the  crucial  study  will  be  the 
IMPROVE-IT study. IMPROVE-IT is a very large 
trial, recently with an expansion of its study group 
from 12,500 patients to 18,000 patients. IMPROVE-IT 
is  an  ongoing  cardiac  events  trial  that  will  enroll 
18,000 patients with recent Acute Coronary Syndrome 
but with relatively low LDL-C values at baseline.28 
Patients  will  be  randomized  to  simvastatin  40  mg 
along with ezetimibe 10 mg versus simvastatin 40 mg 
and placebo. Enrollment has recently been extended 
to be more certain of enough events to determine if 
there is a significant reduction of cardiac events when 
ezetimibe  is  added  to  statin  therapy.28  Thus,  with 
enrollment expected to be completed by mid-summer 
of 2010, we will have to wait several years for a defin-
itive answer to this most important question.29
Finally  there  is  the  SANDS  trial.  SANDS  was 
a long term trial in Type II diabetics, with the goal 
of  using  aggressive  LDL-C  lowering  to  ,71  mg/
dL to reduce carotid IMT.30 SANDS was designed 
to  evaluate  LDL-C  lowering  directly,  producing  it 
with statin alone if possible but with the addition of 
ezetimibe 10 mg when it was needed. The regres-
sion in carotid intima media thickening, or CIMT, 
was  the  same  whether  statin  alone  or  statin  plus 
ezetimibe produced the aggressive LDL-C lowering. Niacin or ezetimibe
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Thus, SANDS   suggests that ezetimibe does not have 
specific negative or positive effects on CIMT regres-
sion/progression, which appears to be affected by the 
LDL-C achieved.30
In summarizing the evidence about the efficacy of 
ezetimibe to reduce cardiovascular events, the only 
clear conclusion is that, until the IMPROVE-IT trial 
is reported several years from now, we will not know 
whether ezetimibe therapy reduces cardiac events or 
not. Therefore, my opinion is that ezetimibe should 
not be utilized as routine therapy when aggressive 
statin therapy can achieve our LDL-C goals. In the 
small number of patients who do not achieve LDL-C 
therapy on maximal statin therapy, such as rosuvasta-
tin 40 mg, then we could consider utilizing ezetimibe 
therapy.  In  my  practice,  I  explain  to  my  patients 
when I want to start ezetimibe that we do not know if 
ezetimibe will reduce their risk of cardiac events as it 
lowers their LDL-C.
side effects of ezetimibe
In  general,  ezetimibe  is  well  tolerated  by  most 
patients.  Side  effects  are  mild  and  generally  self 
limited.22  Reported  side  effects  do  include  modest 
elevations  of  liver  enzymes,  along  with  myopathy 
and even rhabdomyolysis.21
The  most  intriguing  question  about  ezetimibe 
safety is whether ezetimibe might induce the devel-
opment of malignancy. In the SEAS trial, there were 
an increased number of cancers and cancer deaths.26 
A careful examination showed that there was no par-
ticular pattern to the malignancies, and no particular 
organ system involved. The FDA conducted a review 
of this question, reviewing SEAS, IMPROVE-IT, and 
a third study called SHARP. The FDA and indepen-
dent researchers found no increased pattern of malig-
nancy across the three studies.31,32 I think that this 
was just an unusual cluster of random cancers in one 
study, and that it does not represent a true risk factor 
for our patients.
conclusions
In summary, the proper place of ezetimibe in our 
current treatment pattern of hyperlipidemia remains 
unclear. It was quite popular at the outset of its use, 
particularly when it was used in combination with 
simvastatin,  as  the  commercial  product  Vytorin. 
However, it has not, at this time, been properly stud-
ied to document as to whether the LDL-C reduction 
that it produces actually results in reduction of car-
diovascular  events.  In  general,  ezetimibe  appears 
to be safe and well tolerated, with no clear safety 
issues.
This author has always felt that, since any cardiac 
benefit remains unproven, ezetimibe should be used 
only as adjunct therapy in addition to the maximal 
dose of the most potent statin, either rosuvastatin or 
atorvastatin, to lower LDL-C that can not be lowered 
to goal without dual therapy. Whether the patient’s 
cardiovascular risk will be lowered by such therapy 
is unclear. We will not get an answer to this most 
important  question  until  the  IMPROVE-IT  trial  is 
completed and reported in the next several years.
nIAcIn
Niacin, or nicotinic acid, is a B vitamin with cholesterol 
lowering properties. It has enjoyed varying levels of 
interest for its usefulness in managing lipid disorders. 
Its popularity appears to be on the rise, mainly because 
of suggestive results from the ARBITER-6 HALTS 
study, which was discussed previously. Whether this 
surge in popularity will turn out to be justified will 
hinge on the results of the AIM-HIGH study, now in 
progress, which will compare simvastatin/niacin (long 
acting) vs. simvastatin and placebo for the prevention 
of cardiovascular events.33
Mechanism of Action
In spite of its use for the treatment of hyperlipidemia 
for over 50 years, the actual mechanism whereby nia-
cin affects lipid levels is not clear. It is not related to 
its effect as a B vitamin.
effects on Lipid Levels
Niacin has  noticeable effects  on  all of  the signifi-
cant lipid values. Also, the pattern of lipid effect is 
related to the dose level of niacin administered, with 
an increase in HDL-C beginning at lower doses and 
increasing with higher doses. Lowering of LDL-C, 
however, requires much more substantial doses, usu-
ally in the 1500–3000 mg range.34
While the expected effects will vary with the 
preparation  used  and  the  individual  patient,  the 
pattern  of  change  in  the  lipid  fractions  include, 
for the 1000 mg dose, an increase in the HDL-C 
of  about  10%–15%,  a  20%–25%  reduction  in Guthrie
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triglycerides, along with insignificant effect on the 
LDL-C. At the 2000 mg daily dose, the HDL-C 
increase is about 20–30%, along with a 25%–30% 
reduction in triglycerides, and with about a 20% 
reduction in LDL-C. Lp(a) is reduced by 9% at 
1000 mg up to 32% at the 2000 mg dose.34 Higher 
doses, even up to 3000–4000 mg have been used, 
with greater reductions in LDL-C, but they are not 
commonly used now that the statins are available, 
and because of the profound levels of side effects 
that one can see with higher dose niacin.
preparations
Niacin  comes  in  multiple  preparations,  including 
products  that  are  sold  over  the  counter  as  generic 
vitamin or nutritional supplements, along with sev-
eral prescription preparations. If a physician or other 
health  care  prescriber  is  going  to  institute  niacin 
therapy, I would recommend that they utilize one of 
the two major prescription preparations, Niaspan® or 
Slo-Niacin®. In using a prescription preparation, we 
are assured of the quality and accuracy of the FDA 
approved preparation, and this allows the practitioner 
to monitor and regulate the doses used.
Niaspan® is a long acting preparation that comes in 
500 mg, 750 mg. and 1000 mg dose preparations. It is 
given at bedtime, usually at the 500 mg initial dose, 
and slowly titrated. Slo-Niacin® is a generic prepara-
tion with preparations in doses of 250 mg, 500 mg, 
and 750 mg, and it is dosed at bedtime or sometimes 
twice  daily.  Because  of  niacin’s  very  potent  side 
effects, particularly flushing and itching, it needs to 
be initiated at a low dose and titrated up gradually.
Evidence of Efficacy
There  is  widespread  confusion  over  the  efficacy 
data, or lack thereof, around the uses of niacin in the 
prevention of cardiovascular events. Under careful 
examination, the data to support the use of niacin as 
add-on therapy in addition to statin therapy, as it is 
currently used, are essentially non-existent.
The  original  trial  of  niacin  therapy  to  reduce 
coronary events was the Coronary Drug Project, a 
European  trial  published  in  the  1970’s. This  trial 
took very high risk patients with known coronary 
artery disease, and evaluated several different poten-
tial treatments in different groups. In one arm of 
the study, niacin treatment of about 3500 mg daily, 
when compared to placebo, did not reduce total or 
coronary  mortality,  the  primary  endpoint.2  Niacin 
did  reduce  a  single  secondary  endpoint,  namely 
non-fatal  myocardial  infarction.  However,  since 
the overall study was not successful, it is not clear 
evidence of effectiveness to pull out one secondary 
endpoint to claim success. Therefore, the CDP does 
not provide proof of niacin’s effectiveness, even in 
this very high risk group. Also, since the study was 
completed over 35 years ago, when statin therapy 
was in the distant future, what does this unclear data 
say to us now? Unfortunately, there is no clear or 
usable evidence from this very old trial. Also, there 
was a secondary publication from this same trial that 
is even more confusing. Nine years after the study 
was completed and had stopped, the investigators 
went back to the study group and found that there 
was an 11% reduction in total mortality in the niacin 
group.35 However, since the study had been stopped 
and  the  therapy  terminated  nine  years  before  the 
data was evaluated, no one can honestly draw any 
clear conclusion from this data.
Niacin was also a component in several trials of 
combination therapy. However, these studies also fail 
to  give  clear  evidence  of  successful  events  reduc-
tion. Niacin was combined with simvastatin in the 
HATS  study  and  the  combination  was  compared 
against anti-oxidant vitamins or placebo.36 While the 
combination  did  reduce  events  versus  vitamins  or 
placebo, the absence of monotherapy arms for niacin 
or simvastatin alone failed to show whether the addi-
tion of niacin to simvastatin was at all beneficial in 
the reduction of cardiac events instead of the benefit 
being produced completely by the simvastatin.
The CLAS study was an angiographic trial, which 
evaluated the effect of treatment on the progression 
of  coronary  artery  lesions  in  patients  with  known 
disease. In CLAS, niacin was combined with coles-
tipol, a resin binding agent with modest cholesterol 
lowering properties.37,38 The combination therapy did 
slow the progression of coronary lesions, but it did 
not reduce cardiac events, so the overall results are 
unclear. Niacin was shown to reduce cardiac events 
in one Swedish trial when it was combined with the 
fibrate  clofibrate.39  Since  clofibrate  is  now  off  the 
market, that data is not useful to us.
Finally,  we  have  the  previously  mentioned 
ABITER-6-HALTS trial.27Niacin or ezetimibe
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In  ARBITER-6-HALTS,  high  risk  patients 
who  were  already  on  statin  therapy,  with  LDL-C 
,100  mg/dL  and  HDL  ,50  mg/dL  in  men  and 
,55  mg/dL  in  women  were  studied.  Patients  had 
ezetimibe 10 mg or niacin (beginning at 500 mg at 
bedtime  and  aiming  to  titrate  to  2000  mg  at  bed-
time) added to the background statin therapy. Niacin 
additive therapy did reduce the primary endpoint of 
carotid artery intima-media thickening as measured 
by B-mode ultrasound when compared to ezetimibe 
therapy, and there was a significant reduction in car-
diac events in the niacin group with two in the niacin 
group and nine in the ezetimibe group. As I said pre-
viously, the true importance of this study is unclear. 
It could suggest that adding niacin to background sta-
tin therapy will be protective against cardiac events, 
but it could also mean that adding ezetimibe to statin 
therapy increases events. Overall, this study is sug-
gestive and interesting, but not conclusive. Also, tol-
erance of niacin was noticeably less than tolerance of 
ezetimibe in the study.
Overall, clear evidence for the potential benefit of 
niacin therapy in addition to statin therapy awaits the 
AIM-HIGH study. AIM-HIGH will compare simvas-
tatin /niacin versus simvastatin/placebo in high risk 
individuals in a long term trial to evaluate cardiovas-
cular events. When AIM-HIGH is reported, we should 
have much clearer information on whether niacin as 
additive therapy to statin therapy is beneficial.
side effects
Niacin’s  side  effects  remain  a  considerable  factor 
restricting niacin’s widespread use. Although niacin’s 
vitamin status allows it to be sold over the counter, it 
produces a widespread pattern of both symptomatic 
and metabolic side effects.
The  major  symptomatic  side  effect  is  flushing, 
with the attendant pruritis and other forms of skin 
discomfort that accompany it. The actual rates seen 
in  clinical  practice  are  unclear.  The  very  recent 
trial comparing niacin add-on therapy to ezetimibe 
add-on  therapy  found  that  36%  of  niacin  treated 
patients reported flushing and skin symptoms.27 The 
long acting preparations are felt by many to have 
lower rates of skin symptoms, but that is unclear.40 
However, one study, ARBITER-2 using Niaspan®, a 
long acting preparation, had 69% of niacin patients 
complain of skin flushing.41 The main benefit may 
be related to the traditional dosing of the long acting 
preparations at bedtime, allowing some lessening of 
the symptoms during sleep. Also, many practitioners 
think that a small dose of aspirin or an NSAID will 
reduce the dermatological symptoms, but this is also 
unclear.
The considerable metabolic side effects have the 
potential for more severe problems, and those of us pre-
scribing niacin need to take them into consideration.
Liver dysfunction has the potential to be a serious 
side effect of niacin therapy, so that regular monitor-
ing of hepatic enzymes is warranted. The actual rates 
of liver enzyme elevations are not clearly defined. 
They appear to be mild at lower doses but to become 
more prominent above 2000 mg daily.34 The combi-
nation of niacin with a statin can increase the rate of 
elevated liver enzymes.34,36
Glucose elevation is a well known side effect of 
niacin  therapy,  and  it  is  also  related  to  the  niacin 
dose.34 This issue needs to be considered when niacin 
therapy is contemplated in diabetic or glucose intoler-
ant patients.
considerations about combination 
Lipid Therapy
There is increasing interest in combinations of lipid 
lowering agents of different classes to treat complex 
hyperlipidemia. Combination therapy is widely used 
in  treating  many  other  disorders,  such  as  multiple 
agents to lower blood pressure or several different 
antibiotics to treat infections. Since hyperlipidemia is 
different than hypertension and infections, we cannot 
safely assume that combination therapy with differ-
ent lipid lowering classes will be safe and benefi-
cial. Medicine is scientific not logical. Therefore, we 
should need scientific studies rather than intuition to 
drive our therapeutic decisions.
The  lesson  of  torcetrapib  is  very  important  to 
remember. Torcetrapib was a CTEP inhibitor that pro-
duced increases in HDL-C of about 72% coupled with 
a further reduction of about 25% in LDL-C, when it 
was added to atorvastatin therapy. It was assumed that 
these striking effects on these important lipid fractions 
would drastically reduce cardiac disease. In fact, the 
addition of torcetrapib produced significant increases 
in MI and cardiac mortality.42 Therefore, we need to 
be certain that combining two or more lipid reducing 
agents is safe and   furthermore, that it reduces   cardiac Guthrie
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events  rather  than  just  improving  indirect  markers 
like lipid values or arterial intima thickening.
Combination  therapy  with  ezetimibe  to  lower 
LDL-C further than with maximum statin therapy has 
been discussed earlier in this paper. It will remain 
unknown  until  the  IMPROVE-IT  trial  is  reported, 
as to whether this combination offers further events 
reductions over statin therapy. Aggressive lowering 
of LDL-C into the range of 50–55 mg/dl with rosu-
vastatin  therapy  alone  produced  significant  events 
reductions  in  the  JUPITER  study,  so  we  should 
maximize our statin therapy initially before adding a 
secondary LDL-C lowering agent. High dose niacin, 
in doses of 2500 mg or more, or resin binding agents 
like cholestyramine or colestipol can be added to high 
dose statin therapy in very difficult to control patients. 
However, this additional therapy is also unproven to 
reduce events and frequently has unacceptable side 
effects.
Combination therapy with niacin to lower elevated 
triglycerides is attractive to many practitioners. How-
ever, caution here is also in order. While elevated trig-
lycerides add to the risk of elevated LDL-C in patients 
that are not on statin therapy, secondary analyses of 
several of the statin trials indicate that lowering ele-
vated LDL-C with statin therapy eliminates the risks 
of elevated triglycerides.43,44 Other studies have exam-
ined whether elevated triglycerides are actually an 
independent risk factor for increased cardiac events, 
and have determined that they are not a true risk once 
the other abnormal lipid fractions like lower HDL-C 
have been accounted for.45,46,47 Therefore, without at 
least strong evidence that lowering elevated triglyc-
erides in addition to statin therapy actually reduces 
events,  I  recommend  aggressive  LDL-C  lowering 
with maximal statin therapy and using low-fat, low-
carbohydrate diet to reduce triglycerides.
Combination therapy with niacin to increase low 
HDL-C is the most popular and attractive target for 
niacin therapy as added onto statin therapy. Also, sev-
eral studies have shown that, in contrast with elevated 
triglycerides, low HDL-C remains a risk factor for car-
diac events even with most traditional levels of statin 
therapy.48,49 The one exception was from a recent sec-
ondary analysis from the JUPITER study, which low-
ered LDL-C levels down to the 50–55 mg/dL range. In 
that study, super lowering of LDL-C appears to have 
eliminated the additive risk of low HDL-C.50
Previously,  the  AFCAPS-TEXCAPS  trial  had 
used lovastatin therapy alone to prevent initial car-
diac events. In the subgroup of patients with HDL-C 
,40 mg/dl, lovastatin alone had reduced initial car-
diac events by nearly one half.13
Recently,  interest  has  focused  on  adding  niacin 
therapy  onto  statin  treatment  in  patients  with  low 
HDL-C syndrome. The previously mentioned ARBI-
TER-6 HATS and ARBITER-3 trials have shown that 
increasing HDL-C with niacin therapy can improve 
the  surrogate  end-point  of  reducing  carotid  arterial 
wall  intima  thickening.27,51  While  these  studies  are 
interesting and intriguing, they do not offer the clear 
evidence as to whether this addition of niacin to sta-
tin therapy can actually further reduce cardiovascular 
events. This lack of complete clarity is emphasized by 
the older ARBITER-2 and the recently released NIA 
Plaque study.41,52 ARBITER-2 compared adding long 
acting niacin to statin treatment and found only a trend 
toward plaque regression as compared to   placebo.41 
NIA Plaque added niacin or placebo to patients with 
low HDL-C but whose LDL-C was already well con-
trolled on statin therapy.52 In this study, there was no 
difference in regression of intima wall plaque from 
niacin or placebo. This study may support the JUPI-
TER study suggestion that aggressive LDL-C lowering 
may remove the risk effect of low HDL-C.
The resolution of this controversy will await the 
AIM-HIGH  study,  comparing  multi-year  treatment 
with  statin/niacin  versus  statin/placebo  in  patients 
with low HDL-C. At this point, the only conclusion 
that we can make based on clinical trials evidence is 
that aggressive statin therapy will reduce events in 
patients with low HDL-C lipids. Whether adding nia-
cin will be additionally beneficial will remain to be 
seen in the future when AIM-HIGH will be reported.
conclusion
While the temptation to add secondary agents like 
ezetimibe or niacin to statin therapy can be alluring, 
practitioners should remember the questions that we 
have discussed here. Adding either of these second-
ary  agents  has  not  been  proven  to  reduce  cardiac 
events in this add on role. They may be beneficial, 
but again they may not be. What can be said is that 
adding them will increase the cost of therapy (partic-
ularly for ezetimibe) or may significantly increase the 
risk of adverse effects, like the prominent itching and Niacin or ezetimibe
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skin discomfort from niacin. With definitive research 
in progress, it is prudent for practitioners to avoid 
starting these therapies until clear benefit has been 
demonstrated.
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